Skip to main content

Table 2 PICU therapeutic interventions between survivors and non-survivors

From: A case series of children with adenovirus pneumonia: three-year experiences in a tertiary PICU

 

Survivors (n = 56)

Non-survivors (n = 11)

Total (n = 67)

p value

Median of PICU stay, days

11 (7.75, 18)

15 (11, 19.5)

11 (8, 18)

0.861

Median of hospital stay, days

22.5 (16, 34.25)

17 (16, 23.5)

22 (16, 31)

0.124

Co-morbidity, n (%)

 ARDS

27 (48.21%)

9 (81.82%)

36 (53.73%)

0.041

 Liver dysfunction

21 (31.34%)

10 (90.9%)

31 (46.27%)

0.001

 AKI

4 (7.14%)

5 (45.45%)

9 (13.43%)

0.001

 shock

42 (75%)

10 (90.9%)

52 (77.61%)

0.247

 GI dysfunction

31 (55.36%)

11 (100%)

42 (62.69%)

0.005

PICU and hospital therapies, n (%)

 Invasive Mechanical ventilation

51 (91.07%)

11 (100%)

62 (92.54%)

0.303

 CRRT/RRT

11 (19.64%)

8 (72.73%)

19 (28.36%)

<0.001

 ECMO

6 (10.71%)

3 (37.5%)

9 (13.43%)

0.141

 Prone positioning, n (%)

15 (26.79%)

4 (36.36%)

19 (28.36%)

0.519

 Neuromuscular blockade, n (%)

22 (39.29%)

8 (72.73%)

30 (44.78%)

0.041

 Vasoactive use

48 (85.71%)

10 (90.9%)

58 (86.57%)

0.644

 diuretics use

43 (76.79%)

8 (72.73%)

51 (76.12%)

0.773

 Steroids use

55 (98.21%)

11 (100%)

66 (98.51%)

0.655

 IV immunoglobulin

50 (89.29%)

10 (90.9%)

60 (89.55%)

0.872

 Parenteral nutrition

12 (21.43%)

10 (90.9%)

22 (32.84%)

<0.001

 Packed red blood cell perfusion

28 (50%)

10 (90.9%)

38 (56.72%)

0.012

Nosocomial infenctiona, n (%)

15 (26.79%)

7 (63.64%)

22 (32.84%)

0.017

 bacterial

15 (26.79%)

7 (63.64%)

22 (32.84%)

 0.043

 fungal

4 (7.14%)

1 (9.09%)

5 (7.46%)

0.687

  1. aparts of patients complicated with bacteria, mycoplasma pneumoniae or fungi in nosocomial infection or co-infection